Citation

Lam JC, Mason TBA. Curr. Treat. Options Neurol. 2007; 9(6): 404-413.

Copyright

(Copyright © 2007, Current Science)

DOI

10.1007/s11940-007-0042-1

PMID

unavailable

Abstract

Sleep disorder can have a significant impact on the growth and development of children. Behavioral intervention is the first step in the management of many sleep disorders. Limit-setting is particularly challenging in younger children but must be consistent. Good sleep hygiene practices must be emphasized to adolescents as well. Indeed, good sleep hygiene is an important intervention for the entire family. There is an emerging development of pharmacologic treatments for sleep disorders. However, as with most medications used for children, there is a paucity of drugs approved by the US Food and Drug Administration for sleep in children due to the limited number of pediatric clinical trials. As a result, most of what is prescribed has been extrapolated from adult studies and is based on clinical experience. Copyright © 2007 by Current Medicine Group LLC.

Language: en

Keywords

United States; human; hypothermia; insomnia; abdominal pain; sleep; depression; suicide attempt; clinical trial; dissociative disorder; review; fatigue; anorexia; vomiting; mental disease; prescription; weight reduction; clomipramine; cognitive defect; fluoxetine; tachycardia; tricyclic antidepressant agent; venlafaxine; xerostomia; hallucination; somnolence; behavior therapy; paranoia; anxiety disorder; childhood disease; sleep disorder; child development; drowsiness; constipation; gastrointestinal symptom; orthostatic hypotension; appetite; child growth; clonidine; diazepam; confusion; food and drug administration; benzodiazepine derivative; seizure; drug cost; drug receptor binding; diarrhea; nausea; tremor; cost effectiveness analysis; drug withdrawal; hypotension; sweating; dysphoria; diphenhydramine; lorazepam; restlessness; irritability; antihistaminic agent; unindexed drug; eosinophilia; cardiovascular disease; disorientation; hypertension; zolpidem; gabapentin; side effect; hypnotic agent; clinical study; methylphenidate; liver toxicity; clonazepam; drug absorption; drug half life; phototherapy; respiratory failure; drug approval; precocious puberty; modafinil; respiration depression; parasomnia; heart palpitation; carbidopa plus levodopa; melatonin; nervousness; dexamphetamine; bradycardia; blood pressure; positive end expiratory pressure; 5 hydroxytryptophan; motor dysfunction; dizziness; drug hypersensitivity; anticholinergic syndrome; memory disorder; urinary tract infection; tic; dyskinesia; cataplexy; narcolepsy; drug induced headache; sleep apnea syndrome; arousal; pergolide; circadian rhythm sleep disorder; restless legs syndrome; chloral hydrate; budesonide; pramipexole; benzodiazepine receptor; pyrimidine derivative; polysomnography; histamine H1 receptor; actimetry; adenotonsillectomy; dental device; hygiene; hypnagogic hallucination; oxybate sodium; zaleplon